After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for NexImmune Inc. (NEXI) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$0.0749, or +12.59%, to $0.67. Volume reached 6,450 shares, with price reaching a high of $0.66 and a low of $0.6336. Recently, Yahoo Finance discussed the stock, revealing that NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference.
NEXI belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $0.64 and fluctuated between $0.6899 as its day high and $0.5800 as its day low. The current market capitalization of NexImmune Inc. is $18.56M. A total of 1.08 million shares were traded on the day, compared to an average of 1.71M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, NEXI has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 13 BUYs and 0 SELLs from insiders. Insiders purchased 468,257 shares during that period but sold 0.
In the most recent transaction, Verstandig Grant bought 26,876 shares of NEXI for 2.28 per share on Jun 07. After the transaction, the Director now owns 1,105,495 company shares. In a previous transaction on Jun 06, Verstandig Grant bought 25,000 shares at 2.14 per share. NEXI shares that Director owns now total 1,078,619.
Among the insiders who bought shares, Verstandig Grant acquired of 15,000 shares on Jun 03 at a per-share price of $2.22. This resulted in the Director holding 1,053,619 shares of NEXI after the transaction. In another insider transaction, Verstandig Grant bought 47,900 shares at $2.23 per share on Jun 02. Company shares held by the Director now total 1,038,619.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for NEXI in the last 3 months, the mean price target is $3.50 with high estimates of $5.00 and low estimates of $2.00. In terms of 52-week highs and lows, NEXI has a high of $17.56 and a low of $0.57.
As of this writing, NEXI has an earnings estimate of $-0.66 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of $-0.66 per share and a lower estimate of $-0.66. The company reported an EPS of $-0.69 in the last quarter, which was -4.55% lower than expectations of $-0.66.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NEXI is Buy with a score of 4.75. A total of 2 analysts rated the stock as Buy while 2 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.